Skip to main content
Caplight Logo









NeuroSync

NeuroSync

Private
Holliston, MassachusettsHealthcare & Life Scienceshttps://www.neurosync.health/

Last Round

Seed

Mar 11, 2019

Total Funding Raised

$4.13M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

NeuroSync is a neurotechnology company that provides a cloud-based analytics platform for assessing abnormal eye movements to aid in the diagnosis and treatment of various neurological conditions.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical AI, AR/VR Hardware, Sports & Fitness

Business Model

B2B

Customer Profile

Hardware + Subscription, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

concussion diagnosiseye-tracking technologyFDA-cleared medical devicebrain health assessmentconcussion techVR diagnosticstraumatic brain injuryTBIdigital biomarkerneurotechnologymedical AIreturn-to-playcognitive performancesports analyticscognitive fatiguevisuomotor synchronization

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NeuroSync Comparables

Compare NeuroSync with similar companies based on industry and business-model similarity.

NeuroSync comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NeuroFlex
88%
Oculogica
87%
RightEye
84%

NeuroSync Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 11, 2019
Series A ExtensionJan 3, 2018
SeedSep 7, 2017
GrantJun 13, 2017
AcceleratorApr 4, 2017

NeuroSync Investors

Notable investors and investment history

NeuroSync investors
InvestorRounds
Quadrant ManagementSeries A Extension
MassChallenge IsraelGrant, Accelerator
StartUp HealthSeed
Quartus Capital PartnersGrowth Equity
Oceanic PartnersSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 1, 2026

    Grew 32% QoQ, from 38 to 50 employees.

  • Oct 11, 2025

    EyeSync TBI technology has received FDA clearance.

NeuroSync Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NeuroSync Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NeuroSync's valuation, stock price, and market status.

Firmographic Details

HeadquartersHolliston, Massachusetts
Employee Range50
Year Founded2008
Last FundingMar 11, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.